Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zhejiang Taimei Medical Technology Co., Ltd.
浙江太美醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2576)

RE-ELECTION OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The board (the "**Board**") of directors (the "**Directors**") of Zhejiang Taimei Medical Technology Co., Ltd. (the "**Company**") hereby announces that the original term of office of Ms. DONG Xiaohan ("**Ms. Dong**") as an employee representative supervisor of the Company (the "**Employee Representative Supervisor**") will expire on September 21, 2026. Pursuant to the voting results of the employee representatives' meeting of the Company held on June 23, 2026, Ms. Dong was re-elected as the Employee Representative Supervisor of the Company. She will, together with Mr. WEN Gang and Mr. CAI Xin, who were re-elected at the annual general meeting held on June 23, 2026, comprise the third session of the supervisory committee of the Company (the "**Supervisory Committee**"), for a term of three years from June 23, 2026 until the date of expiry of the term of office of the third session of the Supervisory Committee. The biographical details of Ms. Dong are set out below:

Ms. DONG Xiaohan, aged 42, first joined the Group in November 2016 and served as a senior manager of the public relations and marketing division until January 2018. She rejoined the Group in May 2018 and has served as the director of the public relations and marketing division since then. She has served as a supervisor and the chairperson of the Supervisory Committee since July 2024.

Ms. Dong has more than 11 years of experience in marketing. Prior to joining the Group, from July 2007 to June 2008, she was an administrative officer at CIT Finance & Leasing Corporation (美聯信金融租賃有限公司). From June 2008 to June 2010, Ms. Dong worked at and last served as a senior manager at Leo Burnett Black Pen Advertising (Shanghai) Co., Ltd. (李奧貝納黑筆廣告(上海)有限公司), a company principally engaged in the provision of advertising and media services, where she was primarily responsible for project promotion and execution. From August 2010 to February 2011, she was a secretary at Beijing Foreign Enterprise Human Resources Service Co., Ltd. (北京外企人力資源服務有限公司), where she was primarily responsible for administrative matters. From March 2011 to September 2015, she was a marketing manager of the Greater China Region at IMS Market Research Consulting

(Shanghai) Co., Ltd. (艾美仕市場調研諮詢(上海)有限公司), a company principally engaged in the provision of medical science data information and consultancy services, where she was primarily responsible for marketing activities and brand promotion. From October 2015 to November 2016, she worked at Shanghai Huiji Financial Information Services Co., Ltd. (上海匯稷金融信息服務有限公司), a company principally engaged in the provision of finance leases.

Ms. Dong obtained her bachelor's degree in English from Shanghai International Studies University (上海外國語大學) in Shanghai in January 2011.

Ms. Dong will not receive any remuneration for serving as a supervisor, but will receive remuneration in respect of her other position with the Company in accordance with the relevant remuneration and appraisal system of the Company. As the director of the public relations and marketing division of the Company, Ms. Dong is entitled, based on her specific position within the Company and in accordance with the relevant remuneration and appraisal system of the Company, to a monthly salary of RMB87,666, as well as discretionary bonuses, pension plan contributions and share-based payments as provided for in her employment contract, other social security costs, housing benefits and other employee benefits, which are determined by taking into account her background, qualifications, experience, duties and responsibilities within the Group and prevailing market conditions.

As at the date of this announcement, pursuant to Part XV of the Securities and Futures Ordinance, Ms. Dong holds a long position in 185,403 underlying H shares relating to unvested awards granted under the 2026 H Share Award Scheme adopted by the Company on February 14, 2026, representing approximately 0.03% of the Company's total shares in issue and approximately 0.09% of the Company's H shares in issue.

To the knowledge of the Board and the Supervisory Committee, save as disclosed above, Ms. Dong (i) does not hold any position with any other member of the Group; (ii) does not have any relationship with any Director, supervisor, member of senior management, substantial shareholder or controlling shareholder of the Company; (iii) has not held any directorship in any other listed public company during the past three years; and (iv) does not have, or is not deemed to have, any interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As at the date of this announcement, save as disclosed above, the Board is not aware of any other matter relating to the appointment of Ms. Dong that needs to be brought to the attention of the shareholders, nor is there any information required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board
Zhejiang Taimei Medical Technology Co., Ltd.
Dr. ZHAO Lu
Chairman of the Board

Hong Kong, June 23, 2026

As at the date of this announcement, the Board comprises Dr. ZHAO Lu, Ms. WAN Yunyun, Mr. MA Dong, Mr. ZHANG Hongwei, Mr. LU Yiming and Ms. NI Xiaomei as executive Directors, and Dr. JIANG Xiao, Mr. FUNG Che Wai Anthony and Dr. GONG Yan as independent non-executive Directors.